Genmab As Stock Probability of Future Stock Price Finishing Under 25.20
| GMAB Stock | USD 24.33 0.21 0.87% |
Closest to current price Genmab long CALL Option Payoff at Expiration
Genmab |
Genmab AS Target Price Odds to finish below 25.20
The tendency of Genmab Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay under $ 25.20 after 90 days |
| 24.33 | 90 days | 25.20 | about 10.11 |
Based on a normal probability distribution, the odds of Genmab AS to stay under $ 25.20 after 90 days from now is about 10.11 (This Genmab AS probability density function shows the probability of Genmab Stock to fall within a particular range of prices over 90 days) . Probability of Genmab AS price to stay between its current price of $ 24.33 and $ 25.20 at the end of the 90-day period is about 7.95 .
Given the investment horizon of 90 days Genmab AS has a beta of 0.92. This usually indicates Genmab AS market returns are sensitive to returns on the market. As the market goes up or down, Genmab AS is expected to follow. Additionally Genmab AS has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Genmab AS Price Density |
| Price |
Predictive Modules for Genmab AS
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Genmab AS. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Genmab AS's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Genmab AS Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Genmab AS is not an exception. The market had few large corrections towards the Genmab AS's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Genmab AS, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Genmab AS within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.18 | |
β | Beta against Dow Jones | 0.92 | |
σ | Overall volatility | 1.19 | |
Ir | Information ratio | -0.11 |
Genmab AS Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Genmab AS for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Genmab AS can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Genmab AS generated a negative expected return over the last 90 days | |
| Genmab AS is unlikely to experience financial distress in the next 2 years | |
| Genmab AS has a strong financial position based on the latest SEC filings | |
| Latest headline from news.google.com: Genmab AS Shares Acquired by Cubist Systematic Strategies LLC - MarketBeat |
Genmab AS Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Genmab Stock often depends not only on the future outlook of the current and potential Genmab AS's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Genmab AS's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 659.1 M | |
| Cash And Short Term Investments | 28.1 B |
Genmab AS Technical Analysis
Genmab AS's future price can be derived by breaking down and analyzing its technical indicators over time. Genmab Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Genmab AS. In general, you should focus on analyzing Genmab Stock price patterns and their correlations with different microeconomic environments and drivers.
Genmab AS Predictive Forecast Models
Genmab AS's time-series forecasting models is one of many Genmab AS's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Genmab AS's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Genmab AS
Checking the ongoing alerts about Genmab AS for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Genmab AS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Genmab AS generated a negative expected return over the last 90 days | |
| Genmab AS is unlikely to experience financial distress in the next 2 years | |
| Genmab AS has a strong financial position based on the latest SEC filings | |
| Latest headline from news.google.com: Genmab AS Shares Acquired by Cubist Systematic Strategies LLC - MarketBeat |
Additional Information and Resources on Investing in Genmab Stock
When determining whether Genmab AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab AS's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock:Check out Genmab AS Backtesting, Genmab AS Valuation, Genmab AS Correlation, Genmab AS Hype Analysis, Genmab AS Volatility, Genmab AS History as well as Genmab AS Performance. For information on how to trade Genmab Stock refer to our How to Trade Genmab Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genmab AS. If investors know Genmab will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genmab AS listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.07 | Earnings Share 1.26 | Revenue Per Share 29.2127 | Quarterly Revenue Growth 0.296 | Return On Assets 0.1097 |
The market value of Genmab AS is measured differently than its book value, which is the value of Genmab that is recorded on the company's balance sheet. Investors also form their own opinion of Genmab AS's value that differs from its market value or its book value, called intrinsic value, which is Genmab AS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genmab AS's market value can be influenced by many factors that don't directly affect Genmab AS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genmab AS's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genmab AS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genmab AS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.